

E-FILED 09/21/2012

JS-6

UNITED STATES DISTRICT COURT  
CENTRAL DISTRICT OF CALIFORNIA

WENDY McCOOL, individually and  
on behalf of all others similarly  
situated,

Plaintiffs,

vs.

UNIVERSITY MEDICAL  
PHARMACEUTICALS CORP., a  
corporation,

Defendant.

Case No. 2:09-cv-09172-PSG-(FMOx)

CLASS ACTION

**[PROPOSED] ORDER RE JOINT  
STATUS REPORT**

Courtroom: 880

Judge: Hon. Philip S. Gutierrez

Date Filed: November 9, 2009

ELLEN REALSON, on Behalf of  
Herself and All Others Similarly  
Situated.

Plaintiff,

vs.

UNIVERSITY MEDICAL  
PHARMACEUTICALS CORP., a  
California Corporation,

Defendant.

1 CELIA KING-SCOTT, on Behalf of  
2 Herself and All Others Similarly  
3 Situated.

4 Plaintiff,

5 vs.

6 UNIVERSITY MEDICAL  
7 PHARMACEUTICAL CORP., a  
8 California Corporation,

9 Defendant.

10 The Court, having reviewed the Joint Status Report submitted by Plaintiffs  
11 and Defendant on September 17, 2012, and aware of the Notice of Lien filed by  
12 Eagan Avenatti, LLP on February 23, 2012, makes the following determination:

13 IT IS ORDERED that Defendant University Medical Pharmaceuticals should  
14 transfer the settlement funds being held in trust by Defendants' counsel to lead  
15 counsel for Plaintiffs, Newport Trial Group;

16 IT IS ORDERED that Newport Trial Group, after providing individual  
17 payments specified in the parties' agreement to Plaintiffs themselves, shall retain  
18 the attorneys' fees portion of the settlement funds in escrow pending resolution of  
19 the lien noticed by Eagan Avenatti, LLP, and should not until the lien is resolved  
20 expend any of the funds subject to that lien other than here specified;

21 IT IS FURTHER ORDERED that, with both parties representing that  
22 Defendant has complied in full with the terms of the parties' Confidential  
23 Settlement Agreement, that the consolidated actions (*McCool v. University Medical*  
24 *Pharmaceutical Corp.*, *Realson v. University Medical Pharmaceutical Corp.*, and  
25 *King-Scott v. University Medical Pharmaceutical Corp.*) are hereby dismissed with  
26 prejudice.

27 Date: 9/21/12

By: PHILIP S. GUTIERREZ  
Hon. Philip S. Gutierrez